Two-Thirds of Atopic Dermatitis Patients Misdiagnosed, Report Finds
Two out of three patients with atopic dermatitis are misdiagnosed, HCPLive reports — a two-thirds error rate with consequences for therapy, safety and trust.
Topic
Eczema
Topic
Eczema
Bambusa Therapeutics Files for IPO to Fund Eczema Drug Trials
Bambusa Therapeutics has filed for an IPO to fund clinical trials of its eczema drug candidates, joining a crowded atopic dermati…
Bambusa Therapeutics Files for IPO to Bankroll Eczema Drug Trials
Bambusa Therapeutics is preparing an IPO to fund clinical trials of its eczema drug, Briefs Finance reports. Here's what dermatol…
Arcutis Presents ZORYVE Cream Data in Infant Atopic Dermatitis
Arcutis Biotherapeutics presented new clinical data on ZORYVE cream in infants with atopic dermatitis, per Investing.com India. T…
National Eczema Association Releases First National, State-Level AD Report
The National Eczema Association has published the first comprehensive national and state-level report on atopic dermatitis, creat…
National Eczema Association Releases First National and State-Level AD Report
The National Eczema Association has published the first comprehensive report on atopic dermatitis covering both national and stat…
Gut Microbes Emerge as Unexpected Players in Eczema Research
Gut microbes have emerged as unexpected participants in eczema, per Bioengineer.org, extending atopic dermatitis research beyond…
Pfizer Eczema Drug Posts 61% Response as Florida Sues
Pfizer's eczema drug posted a 61% response rate the same day Florida sued the company, creating a split narrative of clinical pro…
Pfizer Eczema Drug Clears Skin in Mid-Stage Trial
Pfizer's experimental eczema drug achieved skin clearance in a mid-stage trial, advancing its atopic dermatitis candidate toward…
Pfizer Reports Significant Skin Clearance with Eczema Drug
Pfizer says its eczema drug shows significant skin clearance in patients, a claim that puts the candidate in the competitive atop…